Preclinical development of an oral anti-Wolbachiamacrolide drug for the treatment of lymphatic filariasis and onchocerciasis

Authors :: Taylor, Mark J.
von Geldern, Thomas W.
Ford, Louise
Hübner, Marc P.
Marsh, Kennan
Johnston, Kelly L.
Sjoberg, Hanna T.
Specht, Sabine
Pionnier, Nicolas
Tyrer, Hayley E.
Clare, Rachel H.
Cook, Darren A. N.
Murphy, Emma
Steven, Andrew
Archer, John
Bloemker, Dominique
Lenz, Franziska
Koschel, Marianne
Ehrens, Alexandra
Metuge, Haelly M.
Chunda, Valerinne C.
Ndongmo Chounna, Patrick W.
Njouendou, Abdel J.
Fombad, Fanny F.
Carr, Robert
Morton, Howard E.
Aljayyoussi, Ghaith
Hoerauf, Achim
Wanji, Samuel
Kempf, Dale J.
Turner, Joseph D.
Ward, Stephen A.
Source :: Science Translational Medicine; March 2019, Vol. 11 Issue: 483
Publication Year :: 2019
Abstract: An oral macrolide drug targeting the bacterial endosymbiont, Wolbachia, shows efficacy against filarial nematodes in preclinical animal models.

Full Text Access

Tools